Tenax Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher T. Giordano
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 101 Glen Lennox Drive Chapel Hill NC United States of America 27517
- IPO Date
- Apr 4, 1994
- CIK
- 0000034956
- Website
- tenaxthera.com
- Similar Companies
- Business
- Tenax Therapeutics, Inc. (Nasdaq: TENX) is a Phase 3 development-stage pharmaceutical company focused on developing novel therapies for cardiopulmonary diseases, particularly pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company develops TNX-103, an oral formulation of levosimendan that has completed Phase 2 trials for PH-HFpEF; TNX-201, an oral enteric-coated imatinib for pulmonary arterial hypertension (PAH); and earlier-stage candidates including TNX-101 and TNX-102 for related pulmonary hypertension indications. Founded in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates primarily in the United States with a small team of experts guiding its clinical programs targeting unmet needs in cardiovascular and pulmonary care. In August 2024, the company closed an oversubscribed $100 million private placement led by BVF Partners LP with participation from Venrock Healthcare Capital Partners, Vivo Capital, Janus Henderson Investors and others to fund the ongoing LEVEL Phase 3 trial of TNX-103 and initiate a second Phase 3 study in 2025, accelerating its path to NDA submission; this followed a $25 million private placement with RTW Investments in March 2025 to support clinical trials and operations.
Company News
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics' heart drug misses main goal in study, shares plunge
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead